BioElectronics Corporation (OTC: BIEL), a developer of medical technology products, released an update from its Chairman, Richard Staelin, PhD, detailing the company's progress in expanding revenues and markets while maintaining disciplined cost control. The company reported a small profit for calendar year 2025, a milestone achieved through relocating offices and reducing staff to better align with operational needs.
The company has initiated targeted advertising campaigns directed at medical professionals and healthcare providers to expand clinical awareness of RecoveryRx among surgeons, pain specialists, rehabilitation providers, chiropractors, and other healthcare professionals seeking non-opioid pain management options. Additionally, BioElectronics expanded its consumer-focused social media advertising with campaigns targeting Generation X consumers to increase brand visibility for drug-free solutions for chronic musculoskeletal pain.
BioElectronics continues outreach to physician-owned ambulatory surgical centers and orthopedic practices to identify a clinical trial partner for RecoveryRx. The objective is to participate in a postoperative clinical study that may support future qualification for reimbursement under the federal NO PAIN Act initiative, which represents a meaningful long-term opportunity for broader adoption of non-opioid pain management technologies in surgical settings.
The company also reports progress in its strategic distribution and licensing relationship with Electrome Corporation. Initial conditions associated with the supply agreement have been satisfied, with BioElectronics receiving Electrome's initial purchase order. Manufacturing activities are underway, and Electrome is planning a commercial launch of BioElectronics' pulsed shortwave therapy products through its platform.
Internationally, BioElectronics is working with legal counsel in Singapore and funders in China regarding arbitration proceedings involving a former distributor believed to have breached its contractual obligations. The company remains committed to protecting its intellectual property, contractual rights, and shareholder interests.
Despite challenges faced by emerging medical technology companies, BioElectronics is encouraged by growing interest in non-drug pain management solutions. The company believes it is well positioned within the evolving electroceutical and non-opioid pain management markets and intends to continue advancing initiatives that support sustainable growth.
